Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched.
Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the Series B round total to $55 million. The company said it plans to use its newly-acquired funds to support the development and clinical evaluation of its closed-loop automated insulin delivery system, Bigfoot Loop, and its connected insulin pen-based decision support system, Bigfoot Inject.
Get the full story at our sister site, Drug Delivery Business News.
The post Bigfoot brings Series B total to $55m with new investment from Abbott appeared first on MassDevice.
from MassDevice https://ift.tt/2GDNvYc
Cap comentari:
Publica un comentari a l'entrada